Condor Provides an Operations Update for Uzbekistan

Condor Provides an Operations Update for Uzbekistan GlobeNewswire January 12, 2026 CALGARY, Alberta, Jan. 12, 2026 (GLOBE NEWSWIRE) — Condor Energies Inc. (“Condor” or the “Company”) (TSX: CDR), a Canadian based, internationally focused energy transition company with active operations in Central Asia is pleased to provide an update on its Uzbekistan operations. Average daily production […]

Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones

Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones GlobeNewswire January 12, 2026 Fourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”),

Bakkt Agrees to Acquire Distributed Technologies Research Ltd.

Bakkt Agrees to Acquire Distributed Technologies Research Ltd. GlobeNewswire January 12, 2026 – Acquisition advances Bakkt's global stablecoin settlement and programmable payments strategy– Company to operate as “Bakkt, Inc.” effective January 22, 2026– Investor Day scheduled for March 17, 2026 at the New York Stock Exchange NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) — Bakkt

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor Company to also participate in Fireside Chat at Lytham Partners 2026 Investor Healthcare Summit on Thursday, January 15, 2026 GlobeNewswire January 12,

Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference

Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 12, 2026 Exceeded 10,000 patients treated to date with CARVYKTI(R) (ciltacabtagene autoleucel; cilta-cel) Increased CARVYKTI(R) manufacturing capacity with the physical expansion of the Raritan facility, now the largest cell therapy manufacturing facility in the U.S. Profitability expected in 2026, driven

Payment Outages Threaten $44.4 Billion in U.S. Retail & Hospitality Sales Annually

Payment Outages Threaten $44.4 Billion in U.S. Retail & Hospitality Sales Annually New Study Reveals U.S. Businesses Average Over 5 Major Outages Annually, with 63% Occurring During Critical Peak Trading Times GlobeNewswire January 12, 2026 Philadelphia, PA and Boston, MA, Jan. 12, 2026 (GLOBE NEWSWIRE) — A new study released today reveals that payment system

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook GlobeNewswire January 12, 2026 Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2 clinical trial studying focal segmental glomerulosclerosis (FSGS) AKB-097 Phase 2 rare kidney disease basket trial scheduled to begin in 2H

Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update

Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update GlobeNewswire January 12, 2026 Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year Introduced 2026 revenue guidance of $58-$62 million Expects to report fourth quarter and full year 2025 financial results on March 2,

The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook

The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook GlobeNewswire January 12, 2026 CERRITOS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based oncology groups in the United States, today reaffirmed 2025 guidance and provided its preliminary 2026 outlook. 2026

Xanadu Strengthens Executive Leadership with Appointment of Chief Financial Officer and Chief Legal Officer

Xanadu Strengthens Executive Leadership with Appointment of Chief Financial Officer and Chief Legal Officer GlobeNewswire January 12, 2026 TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) — Xanadu Quantum Technologies Inc. (“Xanadu”), a leading photonic quantum computing company, today announced the addition of two strategic leaders to their executive team: Michael Trzupek as Chief Financial Officer (CFO)

Scroll to Top